REGISTER

A Multicentre Phase II study of Risk Evaluation in GIST with Slecetive Therapy Escalation for Response.

Share

Trial Status

Completed

Cancer Type

GIST

Aim

To evaluate a risk-modified dose-escalation strategy for patients with advanced GIST based on their underlying KIT mutation status (high-risk: exon 9 / wild type (WT) vs low-risk: exon 11).

Trial Status

Completed

Cancer Type

GIST

Conference Presentation Reference

  1. Kumar SS, Kirkpatrick CM, Mann KP, Ray JE, Graham GG, Williams KM, Day RO, Desai J. Imatinib PKPD relationship: Results from an ongoing study. Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Annual Scientific Meeting; 1–4 Dec 2013; Melbourne.
  2. Desai J, Goldstein D, McArthur G, Hicks R, Fox S, Kotasek D, Kang YK, Bracken K, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. The REGISTER study: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.
  3. Desai J, Kang YK, Kotasek D, Robinson B, McArthur GA, Hicks R, Fox SB, Gebski V, Mann B, Gill RK, Wollin B, Zalcberg JR, Goldstein D. REGISTER: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.

Aim

To evaluate a risk-modified dose-escalation strategy for patients with advanced GIST based on their underlying KIT mutation status (high-risk: exon 9 / wild type (WT) vs low-risk: exon 11).

Principal Investigator

Dr Jayesh Desai